Ensuring trial validity by data quality assurance and diversification of monitoring methods

被引:97
作者
Baigent, Colin [1 ,2 ]
Harrell, Frank E. [3 ]
Buyse, Marc [4 ]
Emberson, Jonathan R. [1 ,2 ]
Altman, Douglas G. [5 ]
机构
[1] Clin Trial Serv Unit, Oxford OX3 7LF, England
[2] Epidemiol Studies Unit, Oxford OX3 7LF, England
[3] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA
[4] IDDI, Louvain, Belgium
[5] Univ Oxford Wolfson Coll, Ctr Stat Med, Oxford OX2 6UD, England
基金
英国医学研究理事会;
关键词
D O I
10.1177/1740774507087554
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Errors in the design, the conduct, the data collection process, and the analysis of a randomized trial have the potential to affect not only the safety of the patients in the trial, but also, through the introduction of bias, the safety of future patients. Trial monitoring, defined broadly to include methods of oversight which begin when the study is designed and continue until it is reported in a publication, has a role to play in eliminating such errors. On-site monitoring can be extremely inefficient for the identification of errors most likely to compromise patient safety or bias study results. However, a variety of other monitoring strategies offer alternatives to on-site monitoring. Each new trial should conduct a risk assessment to identify the optimal means of monitoring, taking into account the likely sources of error, their consequences for patients, the study's validity, and the available resources. Trial management committees should consider central statistical monitoring a key aspect of such monitoring. The systematic application of this approach would be likely to lead to tangible benefits, and resources that are currently wasted on inefficient on-site monitoring could be diverted to increasing trial sample sizes or conducting more trials.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 11 条
  • [1] Are these data real? Statistical methods for the detection of data fabrication in clinical trials
    Al-Marzouki, S
    Evans, S
    Marshall, T
    Roberts, I
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7511): : 267 - 270
  • [2] STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE
    ALTMAN, DG
    BLAND, JM
    [J]. BRITISH MEDICAL JOURNAL, 1995, 311 (7003) : 485 - 485
  • [3] [Anonymous], 2002, Data monitoring committees in clinical trials: A practical perspective
  • [4] Buyse M, 1999, STAT MED, V18, P3435, DOI 10.1002/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.3.CO
  • [5] 2-F
  • [6] European stroke prevention study .2. Efficacy and safety data - Introduction
    Diener, HC
    Forbes, C
    Riekkinen, PJ
    Sivenius, J
    Smets, P
    Lowenthal, A
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 151 : S1 - +
  • [7] Grant AM, 2005, HEALTH TECHNOL ASSES, V9, P1
  • [8] Grant AM, 2005, LANCET, V365, P711
  • [9] ICH, 2007, INT C HARM TECHN REQ
  • [10] *MRC DH JOINT PROJ, 2007, WORKSTR 4 TRIAL MAN